MedPacto announced on the 6th that CEO Kim Sung-jin has been appointed as an adjunct professor at the Yale University School of Medicine.
While there have been cases of professors at Yale serving as research advisors for domestic corporations, this is the first time a CEO of a domestic corporation has been appointed as an adjunct professor at the Yale University School of Medicine.
CEO Kim Sung-jin plans to establish various collaborative relationships with the Yale University medical team regarding the clinical development of innovative drug candidates being developed by MedPacto. He also aims to promote the development of innovative cancer treatments through joint research with world-renowned cancer specialists from Yale.
CEO Kim is a world-class expert in tumor biology. He was the first to identify the critical role of TGF-β (transforming growth factor beta) receptor gene loss and mutations in the carcinogenesis of major human cancers, publishing his findings in international journals such as 'Nature.' He also became the first Korean and the fifth person in the world to decode the human personal genome, along with publishing over 320 papers, including the deciphering of the Korean stomach cancer genome.
From 1987 for 20 years, he served as a distinguished senior researcher at the National Cancer Institute (NCI) under the National Institutes of Health (NIH), and in 2007, he moved to Korea where he held positions such as director of the Gil Medical Center's Cancer and Diabetes Research Institute, director of the CHA Medical College Cancer Research Institute, and director of the Precision Medicine Center at Seoul National University’s Next-Generation Convergence Technology Research Institute. He is currently active as the CEO of MedPacto and the director of the Gil Foundation Research Institute.
A representative from MedPacto said, 'The research and development areas, including pipeline development and clinical trials overseen by CEO Kim Sung-jin, will proceed without any setbacks,' and 'We expect that collaborative research with Yale will greatly assist the company's drug development efforts.'